All Stories

  1. Vaccines Against SARS-CoV-2. Eradicating COVID-19
  2. Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention
  3. A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease
  4. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection
  5. Immunity conferred by drug-cured experimental Trypanosoma cruzi infections is long-lasting and cross-strain protective
  6. Publisher Correction: Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
  7. 51 years in of Chikungunya clinical vaccine development: A historical perspective
  8. A Zika vaccine based on chimpanzee adenovirus ChAdOx1 elicits lineage-transcending sterile immunity and prevents colonisation of brain and ovaries
  9. A probabilistic model of pre-erythrocytic malaria vaccine combination in mice
  10. Rapid travel to a Zika vaccine: are we heading towards success or more questions?
  11. Tailoring aPlasmodium vivaxVaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors
  12. Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
  13. Detecting circulating antibodies by controlled surface modification with specific target proteins: Application to malaria
  14. A highly protective P. vivax CSP vaccine
  15. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
  16. Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
  17. Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles
  18. Tailoring a Combination Preerythrocytic Malaria Vaccine
  19. Acquisition and Longevity of Antibodies to Plasmodium vivax Preerythrocytic Antigens in Western Thailand
  20. Transient IL-10 receptor blockade can enhance CD8+T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen
  21. Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites
  22. Plasmodium vivax malaria vaccines: Why are we where we are?
  23. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
  24. Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques
  25. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
  26. Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
  27. Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity
  28. Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses
  29. Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine
  30. Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
  31. A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP
  32. CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria
  33. Viral vectors as vaccine platforms: deployment in sight
  34. Correction: Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
  35. Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+T-Cell Responses
  36. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime–boost immunisation in non-human primates
  37. Prime-boost vectored malaria vaccines: Progress and prospects
  38. Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses
  39. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria
  40. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors againstPlasmodium berghei
  41. Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A
  42. Viral vector vaccines make memory T cells against malaria
  43. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines
  44. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1
  45. Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier
  46. Human Immunodeficiency Virus Type 1-Specific Immune Responses in Primates upon Sequential Immunization with Adenoviral Vaccine Carriers of Human and Simian Serotypes
  47. CpG Methylation of a Plasmid Vector Results in Extended Transgene Product Expression by Circumventing Induction of Immune Responses
  48. Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier
  49. Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus
  50. Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product
  51. DNA Vaccines.